Skip to content
Directory

Portfolio companies.
34,000+ PE-backed.

Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.

Active deals
25
currently held
Exits tracked
18
hand-checked
Sectors covered
1
across the portfolio
Countries covered
1
from every market
Latest activity
Caledonia Investments1 week ago

Capital Event · capital-cancellation-shares · Capital structure change

capital
Caledonia Investments1 week ago

Capital Event · capital-cancellation-shares · Capital structure change

capital
Caledonia Investments1 week ago

Capital Event · capital-cancellation-shares · Capital structure change

capital
Elaia Partners2 weeks ago

CEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway

admin
Lauxera Capital Partners1 month ago

Board change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board

admin
Ardian1 month ago

Chairman update · Chairman update: du conseil de surveillance Thomas, Patrick · Chairman information updated

admin
BiotechUS
41 companies matching
Soleno Therapeutics
Soleno Therapeutics
Abingworth Bioventures VI
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2018
Hold
8yr
Exit
2026
to Neurocrine Biosciences
Scorpion Therapeutics
Scorpion Therapeutics
Abingworth Bioventures VII
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2020
Hold
5yr
Exit
2025
to Eli Lilly
OnKure Therapeutics
OnKure Therapeutics
Abingworth Bioventures 8
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2023
Hold
1yr
Exit
2024
to Reneo Pharmaceuticals, Inc.
Q32 Bio
Abingworth Bioventures VII
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2020
Hold
4yr
Exit
2024
to Homology Medicines, Inc.
Redpin Therapeutics
4BIO Ventures II
US
Exited
Sector
Biotech
Investor4Bio Partners
Entry
2020
Hold
2yr
Exit
2022
to Kriya Therapeutics
TARA Biosystems
Mérieux Innovation 1
US
Exited
Sector
Biotech
InvestorMerieux Equity Partners
Entry
2019
Hold
3yr
Exit
2022
to Valo Health
eFFECTOR Therapeutics
eFFECTOR Therapeutics
Abingworth Bioventures VI
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2013
Hold
8yr
Exit
2021
to Locust Walk Acquisition Corp.
Aura Biosciences
Columbus Innvierte Life Science Fund I
US
Exited
Sector
Biotech
InvestorColumbus Venture Partners
Entry
2015
Hold
6yr
Owners
3
Exit
2021
Abexxa Biologics
Boehringer Ingelheim Venture Fund
US
Exited
Sector
Biotech
InvestorBoehringer Ingelheim Venture Fund
Entry
2016
Hold
5yr
Exit
2021
to Boehringer Ingelheim
Jasper Therapeutics
Abingworth Bioventures VII
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2019
Hold
2yr
Exit
2021
to Amplitude Healthcare Acquisition Corp.
Vera Therapeutics
Abingworth Bioventures 8
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2021
Hold
0yr
Exit
2021
Spruce Biosciences
Spruce Biosciences
Abingworth Bioventures VII
US
Exited
Sector
Biotech
InvestorAbingworth
Entry
2020
Hold
0yr
Exit
2020
TWIST Bioscience
Mérieux Innovation 1
US
Exited
Sector
Biotech
InvestorMerieux Equity Partners
Entry
2013
Hold
7yr
Exit
2020
to Nasdaq listing (TWST)
KALA BIO
KALA BIO
Ysios BioFund I
US
Exited
Sector
Biotech
InvestorYsios Capital Partners
Entry
2014
Hold
3yr
Exit
2017
BioVex
Ysios BioFund I
US
Exited
Sector
Biotech
InvestorYsios Capital Partners
Entry
2009
Hold
2yr
Exit
2011
to Amgen
Ciphergen Biosystems
Amadeus II Technology Fund
US
Exited
Sector
Biotech
InvestorAmadeus Capital Partners
Entry
2000
Hold
0yr
Exit
2000
Entact Bio
Entact Bio
Abingworth Bioventures 8
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2022
Hold
4yr
Owners
2
Glycomine
Glycomine
Abingworth Bioventures 8
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2019
Hold
7yr
Owners
2
Ray Therapeutics
Ray Therapeutics
Novo Holdings Venture Investments
US
Active
Sector
Biotech
InvestorNovo Holdings
Entry
2021
Hold
5yr
Owners
2
Addition Therapeutics
Addition Therapeutics
Abingworth Bioventures IX
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2025
Hold
1yr
Adicet Bio
Adicet Bio
Abingworth Bioventures VII
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2021
Hold
5yr
Code Biotherapeutics
Code Biotherapeutics
4BIO Ventures III
US
Active
Sector
Biotech
Investor4Bio Partners
Entry
2022
Hold
4yr
Engrail Therapeutics
Engrail Therapeutics
Ysios BioFund III
US
Active
Sector
Biotech
InvestorYsios Capital Partners
Entry
2024
Hold
2yr
Inscripta
Inscripta
Mérieux Innovation 1
US
Active
Sector
Biotech
InvestorMerieux Equity Partners
Entry
2018
Hold
8yr
Launch Therapeutics
Launch Therapeutics
Abingworth Clinical Co-Development Fund 2
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2022
Hold
4yr
March Biosciences
March Biosciences
4BIO Ventures III
US
Active
Sector
Biotech
Investor4Bio Partners
Entry
2024
Hold
2yr
Neurona Therapeutics
Neurona Therapeutics
Ysios BioFund III
US
Active
Sector
Biotech
InvestorYsios Capital Partners
Entry
2024
Hold
2yr
Orbus Therapeutics
Orbus Therapeutics
Abingworth Bioventures VII
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2020
Hold
6yr
QUiCKR Bio
QUiCKR Bio
HCVC Hardware Club Fund II
US
Active
Sector
Biotech
InvestorElephants & Ventures / Hardware Club
Entry
2024
Hold
2yr
Soteria Biotherapeutics
Soteria Biotherapeutics
Abingworth Bioventures VII
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2021
Hold
5yr
Tizona Therapeutics
Tizona Therapeutics
Abingworth Bioventures VI
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2016
Hold
10yr
Trishula Therapeutics
Trishula Therapeutics
Abingworth Bioventures VII
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2020
Hold
6yr
Wugen
Wugen
Abingworth Bioventures 8
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2021
Hold
5yr
cAMPfield
Novo Holdings Seed Investments
US
Active
Sector
Biotech
InvestorNovo Holdings
Entry
2026
Hold
0yr
Owners
2
Antares Therapeutics
Abingworth Bioventures 8
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2025
Hold
1yr
Exicure
Abingworth Bioventures VI
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2019
Hold
7yr
Nido Biosciences
Abingworth Bioventures 8
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2023
Hold
3yr
Pathalys Pharma
Abingworth Bioventures 8
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2023
Hold
3yr
R1 Therapeutics
Abingworth Bioventures IX
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2026
Hold
0yr
Timberlyne Therapeutics
Abingworth Bioventures 8
US
Active
Sector
Biotech
InvestorAbingworth
Entry
2025
Hold
1yr
Zafrens
BlueYard Capital Fund III
US
Active
Sector
Biotech
InvestorBlueYard Capital
Entry
2023
Hold
3yr